'Corporate Reputation of Pharma in 2019 - the Patient Perspective'

IMPACT OF CORONAVIRUS ON PATIENTVIEW STUDY

 

PatientView is closely following developments concerning the coronavirus situation. Since the PatientView organisation already runs on a virtual basis (with all of our team working remotely), we anticipate few, or no, interruptions in PatientView services to customers.

The 'CORPORATE REPUTATION OF PHARMA' 2019 GLOBAL REPORT is based on the findings of a PatientView November 2019-February 2020 survey. The report will be published on Tuesday, 21st April 2020. Given that the pharmaceutical industry has been propelled even further into the public eye by the coronavirus pandemic, PatientView survey findings will help influence pharma's understanding of public trust in the industry, and assist companies in their corporate-reputation strategies as the coronavirus crisis continues.

 

CORPORATE REPUTATION OF PHARMA, 2019 (publication 21st APRIL 2020)

 

If you have not done so already, book your preview now (at no extra cost!) ...

... before the official publication date, and the release of headline findings to the media. 

Publication date is Tuesday, 21st April 2020.

 

Smooth looking dash
 
 

About 2019's respondent patient groups

  • 1,850 patient groups worldwide responded to the 2019 'Corporate Reputation of Pharma' survey — the highest response rate in the survey's nine-year history.

2019's respondent patient groups specialise in 124 therapy areas

 

Footnote:

  • Autoimmune includes: arthritis; atopic dermatitis/eczema; coeliac; Crohn’s and colitis; lupus; psoriasis; and scleroderma.
  • Cancer includes: bladder; blood; brain; breast; children’s /young people's; digestive; head and neck; kidney; lung; men's; ovarian; pancreatic; prostate; rare; skin; thyroid; and women’s.
  • Circulatory includes: heart; heart/lung; hypertension; thrombosis; and stroke.
  • Endocrine includes: adrenal; diabetes; thyroid; and pituitary.
  • Mental health includes: ADD/ADHD; addiction; anxiety; bipolar disorder; depression; and schizophrenia.
  • Neurological includes: ataxia; brain injuries/disorders; dementia/memory disorders; epilepsy; fibromyalgia; migraine/other headache disorders; multiple sclerosis; pain; and Parkinson’s.
  • Respiratory includes: allergy; asthma; COPD; cystic fibrosis; pulmonary fibrosis; and pulmonary hypertension.
 

2019's respondent patient groups are headquartered in 95 countries

Patient groups from the countries coloured in green responded to the 2019 survey

About the companies assessed by 2019's respondent patient groups

 
  • 48 pharma companies are assessed by the respondent patient groups for the companies’ performance at 12 key indicators that impact corporate reputation. The number of 2019’s respondent patient groups familiar, and working, with each company can be seen in the table below.
 

The 12 key indicators used to assess corporate reputation

  1. Patient centricity.
  2. Patient information.
  3. Patient safety.
  4. Products of most benefit to patients.
  5. Transparency: pricing.
  6. Transparency: clinical-trial data.
  7. Transparency: funding of stakeholders.
  8. Integrity.
  9. Quality of relationships with patient groups.
  10. Providing services ‘beyond the pill’.
  11. Engaging patients in research.
  12. Engaging patients in development.
 

WHAT THE APRIL 2020 GLOBAL REPORT WILL CONTAIN

 

Industry-wide analyses

  • Patient groups' perceptions of the corporate reputation of the pharma industry as a whole (compared with that of other healthcare industries).
  • The pharma industry's corporate reputation, 2011-2019.
  • How the pharma industry as a whole has performed, 2011-2019, at various activities of importance to patients and patient groups.
  • Types of relationships between the respondent patient groups and pharmaceutical companies.
 

Company analyses

  • Familiarity of respondent patient groups with each company (corporate brand awareness).
  • The numbers of patient-group partners for each company. Plus, the major types of working relationships that your company—and the other companies—have with these patient groups.
  • Company scores and rankings for the 12 indicators of corporate reputation.
  • Historical data on each company's rankings, 2019 v. 2018.
  • Net Promoter Score.
  • The other pharma companies with which a company's patient-group partners work.
 
 

For further information on this report, please use contact details below

 
FacebookTwitterLinkedInWebsite
Alexandra Wyke
PatientView
Mobile/cell: 0044-(0)7960-855-019
e-mail: report @ patient-view.com
Registered in England Number: 3944382 
Registered office:  
One Fleet Place, London, EC4M 7WS, UK
Unsubscribe